Draft:Andrew Dick
British ophthalmologist
From Wikipedia, the free encyclopedia
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 2,927 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Andrew D Dick (Professor)
Andrew Dick is Duke Elder Chair and Director of UCL Institute Ophthalmology. He is also Professor of Ophthalmology at the University of Bristol, co-Director of NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology[1], as well as non-executive director at Moorfields Eye Hospital.
Career
Professor Dick studied medicine (MBBS) with a degree in Biochemistry BSc (Hons) from Charing Cross and Westminster Medical School and the University of London. He spent an MRC sponsored summer sabbatical in Biochemistry with Professor Coleman at Yale. He undertook MRCP training prior to entering ophthalmology residency and lectureship with Professor John Forrester at the University of Aberdeen, Scotland to further his science and clinical training. During this period, he was awarded an MRC Post Doctoral Travelling Fellowship to work with Dr Jon Sedgwick at the Centenary Institute of Cancer Medicine and Cell Biology in Sydney Australia. He returned to the UK to take up Clinical Senior Lectureship at the University of Aberdeen until his move to the University of Bristol in 2000 as Chair and Professor of Ophthalmology. Since 2016 he has been Director of UCL Institute of Ophthalmology and Duke Elder Chair of Ophthalmology, UCL.[2]
Research
Professor Dick’s scientific impact stems from his early work on cytokines and mechanisms of tissue damage, including TNFalpha and the role of microglia in ocular inflammation (uveitis) and age-related macular degeneration (AMD). The work has delivered new insights into the pathogenesis and new approaches to treatment of this group of important blinding diseases. He has been instrumental in taking these insights through to novel treatments. During the 1990s, he was one of the pioneering contributors to the global implementation of biologic therapy for uveitis in ophthalmology.
His ongoing bench-to-bedside approach has been instrumental in generating the data and role of TNF-mediated inflammation in the retina. This work provided the scientific and preclinical foundation that led to co-leading pivotal and regulatory Phase III clinical trials (NIHR and ARUK-funded): SYCAMORE trial[3] and collaborations with pharmaceutical partner AbbVie on the VISUAL trials in adults.[4] These efforts led to FDA approval and commissioning of adalimumab (anti-TNF therapy) for the treatment of non-infectious ocular inflammatory disease world-wide in children and in adults.
He has expanded his work to better understand the regulation of immune homeostasis and disruption, and age and sex differences. This has led to novel pathway discoveries and the co-founding of a University of Bristol Spin Out, Cirrus Therapeutics Inc.[5], to develop therapy for age-related Macular Degeneration and ocular inflammatory disease, that is based in Boston and Singapore.
Awards
In 2007 Professor Dick was awarded the Fellowship of Academy of Medical Sciences[6] for exceptional contribution to the advancement of medical science. In 2011 he received the Alcon Research Institute Award for outstanding contributions in the field of vision research. In 2023 he received the Fellowship of European association for Vision and Eye Research (EVER)[7] and Gold Fellowship of Association for Research in Vision and Ophthalmology (ARVO). He served as President of the EVER Association in 2017 and as Vice President of ARVO in 2019.